Insider · CIK 0001619961
Ian Mortimer
ceopresidentofficerdirectorcfo
Files at XENE (Xenon Pharmaceuticals Inc.). First filing Oct 1, 2025, latest Oct 1, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 6
$1.1M bought, $21M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XENE: Xenon Pharmaceuticals Inc.
XENEOct 9, 2026 · close 36.44
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 86Strong | Xenon Pharmaceuticals Inc. | $1.1M 30,000 shares | +151% | +2% from low-48% from high | |
| 31Weak | Xenon Pharmaceuticals Inc. | $404k 7,308 shares | -27% | +96% from low-12% from high | |
| 50Moderate | Xenon Pharmaceuticals Inc. | $17M 281,269 shares | -347% | +122% from low0% from high | |
| 35Weak | Xenon Pharmaceuticals Inc. | $1.8M 40,000 shares | -87% | +58% from low-3% from high | |
| 50Moderate | Xenon Pharmaceuticals Inc. | $1.1M 25,205 shares | -81% | +59% from low0% from high | |
| 5Weak | Xenon Pharmaceuticals Inc. | $4,366 97 shares | -0% | +58% from low0% from high | |
| 25Weak | Xenon Pharmaceuticals Inc. | $1.0M 25,000 shares | -44% | +39% from low-14% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | XENE Xenon Pharmaceuticals Inc. | POpen-market purchase Common Shares | +30,000 | $37.38 | $1.1M | 49,923 | 11 d ago |
| Mar 12, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Common Shares10b5-1 | +12,500 | - | - | 27,231 | Mar 13, 2026 |
| Mar 13, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -7,308 | $55.23 | $404k | 19,923 | Mar 13, 2026 |
| Mar 12, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Restricted Share Unitsderivative10b5-1 | -12,500 | $0.00 | $0 | 37,500 | Mar 13, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Common Shares10b5-1 | +75,000 | $8.40 | $630k | 81,000 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -21,791 | $58.81 | $1.3M | 59,209 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -31,694 | $59.88 | $1.9M | 27,515 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -21,515 | $60.49 | $1.3M | 6,000 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Common Shares10b5-1 | +25,000 | $3.10 | $78k | 31,000 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -12,479 | $59.50 | $743k | 18,521 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -10,072 | $60.47 | $609k | 8,449 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -2,449 | $61.26 | $150k | 6,000 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Common Shares10b5-1 | +105,000 | $4.75 | $499k | 111,000 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -43,348 | $59.26 | $2.6M | 72,652 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -61,652 | $60.08 | $3.7M | 6,000 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Common Shares10b5-1 | +65,000 | $9.44 | $614k | 71,000 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -65,000 | $62.06 | $4.0M | 6,000 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Common Shares10b5-1 | +20,000 | - | - | 26,000 | Mar 11, 2026 |
| Mar 10, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -11,269 | $60.11 | $677k | 14,731 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Stock Optionderivative10b5-1 | -75,000 | $0.00 | $0 | 0 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Stock Optionderivative10b5-1 | -25,000 | $0.00 | $0 | 0 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Stock Optionderivative10b5-1 | -105,000 | $0.00 | $0 | 0 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Stock Optionderivative10b5-1 | -65,000 | $0.00 | $0 | 0 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Performance Share Unitsderivative10b5-1 | +20,000 | $0.00 | $0 | 20,000 | Mar 11, 2026 |
| Mar 9, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Performance Share Unitsderivative10b5-1 | -20,000 | $0.00 | $0 | 0 | Mar 11, 2026 |
| Jan 9, 2026 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Share Option (Right to Buy)derivative | +350,000 | $0.00 | $0 | 350,000 | Jan 9, 2026 |
| Jan 9, 2026 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Restricted Share Unitsderivative | +65,000 | $0.00 | $0 | 65,000 | Jan 9, 2026 |
| Jan 2, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Common Shares10b5-1 | +40,000 | $7.49 | $300k | 46,000 | Jan 2, 2026 |
| Jan 2, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -37,938 | $44.40 | $1.7M | 8,062 | Jan 2, 2026 |
| Jan 2, 2026 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -2,062 | $44.93 | $93k | 6,000 | Jan 2, 2026 |
| Jan 2, 2026 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 0 | Jan 2, 2026 |
| Dec 5, 2025 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -14,375 | $45.03 | $647k | 16,830 | Dec 9, 2025 |
| Dec 8, 2025 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -8,820 | $45.59 | $402k | 8,010 | Dec 9, 2025 |
| Dec 8, 2025 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -2,010 | $46.32 | $93k | 6,000 | Dec 9, 2025 |
| Nov 28, 2025 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -97 | $45.01 | $4,366 | 31,205 | Dec 3, 2025 |
| Oct 1, 2025 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Common Shares10b5-1 | +25,000 | $7.69 | $192k | 56,302 | Oct 1, 2025 |
| Oct 1, 2025 | XENE Xenon Pharmaceuticals Inc. | SOpen-market sale Common Shares10b5-1 | -25,000 | $40.16 | $1.0M | 31,302 | Oct 1, 2025 |
| Oct 1, 2025 | XENE Xenon Pharmaceuticals Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 0 | Oct 1, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.